| Document |
Document Title |
|
JP5710246B2 |
The invention further contemplates the corresponding metal-chelate complexes as well as pharmaceutical compositions thereof, and their uses in diagnostic imaging and radiotherapy.
|
|
JP2015078229A |
To provide lipids-therapeutic nucleic acid compositions useful for general therapeutic use.The present invention provides novel cationic lipids and lipid particles comprising the same. The lipid particles can further comprise active phar...
|
|
JP2015078205A |
To provide a pharmaceutical composition for treating bone loss by binding to an osteoprotegerin ligand (OPGL).The invention provides a pharmaceutical composition for treatment of bone loss which contains an antibody containing H chain an...
|
|
JP5706926B2 |
The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of sele...
|
|
JP5693950B2 |
The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within ...
|
|
JP2015057408A |
To provide pharmaceutical compositions for treating bone loss.A pharmaceutical composition contains fully humanized antibody molecules that can regulate activity of an osteoprotegerin ligand (OPGL). The antibody molecules inhibit osteocl...
|
|
JP5675758B2 |
Crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid are new. Independent claims are also included for: (1) crystalline calcium salt of 5-methyl-(6S)- and -(6R)-tetrahydrofolic acid; and (2) the preparation of cry...
|
|
JP5675759B2 |
Crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid are new. Independent claims are also included for: (1) crystalline calcium salt of 5-methyl-(6S)- and -(6R)-tetrahydrofolic acid; and (2) the preparation of cry...
|
|
JP5675760B2 |
Crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid are new. Independent claims are also included for: (1) crystalline calcium salt of 5-methyl-(6S)- and -(6R)-tetrahydrofolic acid; and (2) the preparation of cry...
|
|
JP2015501793A |
Compounds of formula I as shown below and as defined herein: pharmaceutically acceptable salts thereof, synthetics, intermediates, formulations, and cancers using them, eg, at least partially driven by RSK. Or a method of treating a dise...
|
|
JP5634990B2 |
In one aspect, the invention provides compounds of Formula I or pharmaceutically acceptable salts thereof. In another aspect, the invention provides methods for treatment of diseases or disorders mediated by a protein kinase, comprising ...
|
|
JP5600116B2 |
Provided are compounds of Formula Ia: pharmaceutically acceptable salts thereof, compositions containing such compounds, and such compounds for use in the treatment of a hepatitis B viral infection.
|
|
JP5587914B2 |
Disclosed are small molecule inhibitors of the formula (I), which are useful in treating various diseases and conditions involving chymase.
|
|
JP5576903B2 |
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount...
|
|
JP5552422B2 |
(6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid calcium salt aqueous solution production involves methylating (6S)-5,6,7,8-tetrahydrofolic acid with a part of the corresponding (6R)-diastereoisomer in the range of 4-8 wt.% in water. Calciu...
|
|
JP5541859B2 |
The present invention relates to polymers comprising a repeating unit of the formula (I), and their use in electronic devices. The polymers according to the invention have excellent 5 solubility in organic solvents and excellent film-for...
|
|
JP5513119B2 |
Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or prevent...
|
|
JP5498786B2 |
The present invention provides a novel compound having an agonist action at AT 2 receptor and expected as a pharmaceutical product, and also provides a method of treating or preventing various diseases. The novel sulfonyl malonamide deri...
|
|
JP5492920B2 |
Dihydropteridinone derivatives (I) are new. Dihydropteridinone derivatives of formula (I) and their tautomers, isomers, acid addition salts, solvates and hydrates are new. L : a bond, A, OA or N(R 7>)A; A : 1-6C alkylene, 2-6C alkenylene...
|
|
JP5464685B2 |
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds ...
|
|
JP5448284B2 |
The invention provides a conjugate comprising ethylenedicysteine (EC) conjugated to neomycin.
|
|
JP5400791B2 |
Dihydropteridin-6-one derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds o...
|
|
JP5368099B2 |
The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of sele...
|
|
JP5360748B2 |
To provide an anti-trypanosome agent, a remedy for trypanosomiasis, and a method for suppressing proliferation of Trypanosoma brucei. It has been found that vitamin B2 has concentration-dependent proliferation suppressing effect on Trypa...
|
|
JP2013540768A |
A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and pot...
|
|
JP5308342B2 |
Disclosed is a compound which is useful as a prophylactic or therapeutic agent for a sex hormone-dependent disease or the like. Specifically disclosed are: a nitrogenated fused-ring derivative which is represented by the general formula ...
|
|
JP5289935B2 |
Methods for purifying pteroic acid, analogs of pteroic acid, and derivatives of pteroic acid are described. Methods for synthesizing and purifying conjugates of vitamins, including FITC conjugates of folic acid, folic acid analogs, and d...
|
|
JPWO2012011591A1 |
INDUSTRIAL APPLICABILITY The present invention is useful for the prevention / treatment of ecosanoid-related diseases such as arteriosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis,...
|
|
JP5271677B2 |
Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenograft models for their efficacy against human tumors are shown to be far superior to methotexate ("MTX") and are even superior to the newer ...
|
|
JP5261487B2 |
The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-
4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1...
|
|
JP5232083B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
JP5220968B2 |
Compositions comprising one or more active ingredients and, optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaires, wherein the active ingredients consist of a) a component A consisting ...
|
|
JP2013523811A |
The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives.
|
|
JP5211068B2 |
The present invention relates to 4,5-ring annulated indole derivatives of formula (I), compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treatin...
|
|
JP5202774B2 |
Crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid are new. Independent claims are also included for: (1) crystalline calcium salt of 5-methyl-(6S)- and -(6R)-tetrahydrofolic acid; and (2) the preparation of cry...
|
|
JP2013518879A |
The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position....
|
|
JP2013515734A |
The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositi...
|
|
JP5184783B2 |
Process for the preparation of tetrahydrobiopterin from neopterin and/or 6-substituted pterins with an improved yield and a high stereoselectivity. Also disclosed herein are novel individual intermediates prepared in the preparation of t...
|
|
JP5164574B2 |
Fused piperazin-2-one derivatives are prepared by hydrogenating with hydrogen in the presence of a hydrogenation catalyst and a specified compound; and adding a copper, iron or vanadium compound, where the hydrogenating and adding steps ...
|
|
JP2013505927A |
A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the pr...
|
|
JP5121105B2 |
Process for the preparation of tetrahydropterin and tetrahydropterin derivatives by hydrogenating pterin and pterin derivatives with hydrogen in the presence of a hydrogenating catalyst, in which the hydrogenation is carried out in a pol...
|
|
JP5102021B2 |
The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) wherein the groups R1 to R7, R10 and R11 have the meanings given in the claims and specification, the isomers thereof, methods of preparing thes...
|
|
JP2012532126A |
The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
|
|
JP5094391B2 |
Disclosed are processes for preparing dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and in the specification.
|
|
JP2012232990A |
To provide an improved process for preparation of dihydropteridinone.The process for preparation of a dihydropteridinone derivative is illustrated by the reaction example.
|
|
JP5079969B2 |
A synthetic process is disclosed for coupling amino acids to a substrate. The process involves dissolving the amino acid and the scaffold in a non-polar aprotic solvent, and agitating the resulting mixture for a predetermined time. The p...
|
|
JP5065529B2 |
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount...
|
|
JP5069463B2 |
The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermed...
|
|
JP5066756B2 |
[Problem] To provide means for improving symptoms of cerebral dysfunction. [Solution Means] The inventor has newly found that peripheral administration of sepiapterin increases the bioavailability of aromatic monoamines in the brain. Acc...
|
|
JP2012211178A |
To provide a compound for the treatment of various cancer diseases.The invention relates to the use of a specified dihydropteridinone compound, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures t...
|
